The multi-million euro round is led by High-Tech Gründerfonds (HTGF) and Bayern Kapital. Auxxo and another institutional investor are also participating. The company did not disclose the exact amount of funding.
The Munich startup plans to use the fresh capital to advance certification as a medical device class IIa and bring the first therapy modules to market maturity. The goal is to make muscle health transparent, personalized, and affordable for everyone.
Platform for muscle diagnostics and stimulation
According to Noxon, the technology combines continuous muscle diagnostics with neuromuscular electrical stimulation in an everyday-use wearable for the first time. The goal is a closed feedback loop consisting of real-time measurement and personalized muscle and nerve activation throughout the entire course of therapy. According to the company’s own information, pilot studies are currently underway, and another clinical trial is planned.
In rehabilitation and neuromuscular diseases, diagnostics and muscle activation have so far been mostly carried out at specific points under clinical conditions. This results in a lack of continuous data from everyday life. Noxon aims to remedy this. According to the company, textile-based sensor and stimulation elements can be integrated into existing products such as tapes, patches, or orthopedic aids.
This could not only treat tremor in Parkinson’s patients, but also restore motor functions after paralysis and perform performance analyses in elite sports.
Maria Neugschwender, CEO of Noxon, says:
“Neurological and musculoskeletal diseases are increasing worldwide. Healthy muscle function is fundamental, yet remains a blind spot for many.”
The support from investors enables the platform to be further clinically validated and first products to be brought to market, according to Neugschwender.
Pilot projects with clinical partners
In parallel, Noxon is working with medical partners on pilot applications. These include the University Hospital Würzburg and the neuroscience group N-Squared Lab. The focus is on applications where signal transmission between brain and muscle is impaired. These include solutions to reduce Parkinson’s tremor, among others.
Investors also see potential in the platform. Dr. Lena-Sophie Schütter, investment manager at HTGF, says:
“What convinces me about Noxon is that effective therapy becomes as simple as putting on a bandage.”
According to the company, Noxon’s modular platform addresses a market of more than 1.1 billion people with muscle-related diseases worldwide. With the support of early-stage investors from the Bavarian ecosystem, the Munich startup is now working on the next stage of development. If clinical validation succeeds, Noxon could transfer its technology from Munich to further applications.
